Wixela Inhaler vs Advair: Uses, Side Effects, and Cost

Wixela Inhub is a generic dry powder inhaler that delivers the same two medications found in the well-known brand Advair Diskus: fluticasone propionate, an inhaled corticosteroid, and salmeterol, a long-acting bronchodilator. It was approved by the FDA in 2019 as the first substitutable generic for Advair Diskus, meaning pharmacists can swap one for the other without requiring a new prescription.¹ For the millions of people who rely on a fluticasone-salmeterol combination to manage asthma or chronic obstructive pulmonary disease (COPD), Wixela offers a clinically equivalent option at a substantially lower price, though it comes with its own device to learn and the same side-effect profile to manage.

What Wixela Treats and Who It Is For

Wixela is prescribed for two main groups. The first is adults and children (aged four and older) with asthma whose symptoms are not adequately controlled by an inhaled corticosteroid alone. The second is adults with COPD who are at high risk for flare-ups, sometimes called exacerbations.² In both conditions, the goal is the same: reduce airway inflammation and keep the airways open so that breathing stays easier day to day and acute episodes become less frequent.

Wixela comes in three strength levels, matching the three Advair Diskus strengths: 100/50, 250/50, and 500/50 (the first number is micrograms of fluticasone propionate, the second is micrograms of salmeterol). Your doctor picks the strength based on disease severity. For asthma, the lowest effective dose is preferred to minimize side effects. For COPD, the 250/50 strength is the one most commonly studied and used.

How the Two Drugs Work Together

The combination works because each medication targets a different part of the problem. Fluticasone propionate is a corticosteroid that dials down the chronic inflammation driving both asthma and COPD. In the airways of people with COPD, for example, fluticasone has been shown to sharply reduce mucosal mast cells, a type of immune cell that triggers inflammatory cascades.³ By dampening the immune response in the lining of the airways, it reduces swelling, mucus production, and the hyperreactivity that leads to sudden breathing difficulty.

Salmeterol handles the other half. It is a long-acting beta-2 agonist, meaning it relaxes the smooth muscle wrapped around the airways and keeps them dilated for roughly twelve hours per dose. Beyond simple bronchodilation, salmeterol also reduces leakiness in the blood vessels lining the airways, tamps down the release of inflammatory chemicals from mast cells, and stimulates the tiny cilia that sweep mucus upward out of the lungs.⁴ Together, the corticosteroid tackles the underlying inflammation while the bronchodilator keeps the airways physically open, and each enhances the other’s effects in ways that neither achieves alone.

Bioequivalence to Advair Diskus

For a generic inhaler to be approved as substitutable, the FDA requires more than just the same active ingredients. Because inhaled drugs act locally in the lungs, the generic device has to deliver the medication to the same place, in the same amounts, with the same therapeutic effect. This is more complex than proving bioequivalence for a generic pill, where you mainly need to show the drug gets into the bloodstream at the same rate. For Wixela, the manufacturer had to demonstrate equivalent systemic drug exposure and equivalent lung function outcomes in clinical studies.⁵

In a head-to-head clinical trial with adults who had asthma, Wixela met the FDA’s bioequivalence criteria on both primary measures of lung function. The therapeutic effects in the lungs were statistically equivalent to Advair Diskus, and both inhalers were well tolerated.⁶ The FDA’s approval pathway for generic inhalers is sometimes called a “weight-of-evidence” approach, combining laboratory bench testing, blood-level studies, and clinical lung-function studies to build the full case that the generic performs like the brand.⁷

Real-World Evidence After Switching

Bioequivalence trials take place under controlled conditions, so a fair question is whether the generic performs the same in everyday clinical practice, where patients have varying technique, different disease severity, and fewer reminders to use their inhaler correctly. A large observational study compared outcomes in over 45,000 patients with COPD who used either Advair Diskus or Wixela Inhub. After careful statistical matching, the researchers found virtually no difference: the risk of a moderate or severe COPD flare-up was nearly identical between groups, and the rate of pneumonia hospitalization was the same as well.⁸ For patients who worry about being switched from a brand they trust, this is reassuring evidence that real-world outcomes don’t suffer with the generic.

How Well the Fluticasone-Salmeterol Combination Works

Because Wixela delivers the same drug combination as Advair, decades of research on fluticasone-salmeterol apply directly. In asthma, the combination substantially outperforms either component on its own. A year-long trial found that only about 4% of patients on the combination experienced two or more exacerbations, compared with roughly 17% on fluticasone alone and 40% on salmeterol alone.⁹ Another trial showed the combination improved lung function by about 0.20 liters in twelve weeks, a meaningful gain for someone struggling to breathe.¹⁰

In COPD, the picture is similarly strong. A study of nearly 800 patients found that the fluticasone-salmeterol combination reduced moderate-to-severe exacerbations by about 30% compared with salmeterol alone, and cut the rate of exacerbations requiring oral steroids by 40%.¹¹ Reviews of the evidence have consistently confirmed that the combination improves both lung function and quality-of-life scores beyond what either drug achieves on its own.¹²

Where Wixela Fits Among Newer Alternatives

The respiratory drug landscape has shifted since fluticasone-salmeterol first came on the market. For COPD in particular, newer dual-bronchodilator combinations that pair a different type of long-acting bronchodilator with a long-acting muscarinic antagonist have shown they can outperform fluticasone-salmeterol in certain patients. A large trial found that one such combination reduced the annual rate of all COPD exacerbations by 11% compared with salmeterol-fluticasone and delayed the time to a first exacerbation by about three weeks.¹³ Triple-therapy inhalers, which bundle three drugs into a single device, have also shown advantages over simply doubling the dose of an inhaled corticosteroid-plus-bronchodilator regimen like Wixela, particularly for patients with frequent exacerbations.¹⁴

None of this makes Wixela obsolete. Many patients with asthma or COPD are well controlled on two drugs and do not need the added complexity or cost of triple therapy. For COPD patients with frequent exacerbations despite dual bronchodilator therapy, or those with elevated eosinophil counts suggesting an inflammatory component, fluticasone-salmeterol remains a guideline-supported option. In asthma, the combination is still a mainstay at moderate-to-severe treatment steps. And compared with substituting a leukotriene modifier for salmeterol, the combination with salmeterol has shown at least equivalent protection against asthma exacerbations over a full year, with a slightly greater improvement in lung function.¹⁵

Side Effects to Be Aware Of

Because Wixela delivers the same drugs as Advair, it carries the same side-effect profile. The most common issues stem from the corticosteroid component landing in the mouth and throat rather than reaching the lungs. Oral thrush (a yeast infection of the mouth) and hoarseness are the two most frequently reported local side effects. A meta-analysis found that dry powder inhalers carrying corticosteroids roughly triple the odds of oral thrush compared with placebo, and carry a similar increase in the risk of hoarseness.¹⁶ Rinsing your mouth with water and spitting after every dose is the single most effective step to prevent both problems. A review of preventive strategies confirmed that poor oral hygiene and improper inhaler use raise the risk considerably.¹⁷

On the systemic side, fluticasone propionate is designed to have minimal absorption beyond the lungs, but at higher doses or with long-term use, it can suppress the body’s natural cortisol production. Fluticasone propionate has been shown to produce dose-dependent suppression of the body’s stress-hormone axis, more so microgram-for-microgram than some other inhaled corticosteroids.¹⁸ In rare cases, even standard doses have caused clinically significant adrenal insufficiency, with fatigue as the main symptom.¹⁹ This is uncommon, but worth flagging for anyone on the 500/50 strength or using additional steroid medications.

The salmeterol component can cause tremor, headache, and a racing heartbeat. A large safety study focusing specifically on salmeterol at its standard dose found no increased risk of cardiovascular events compared with placebo in COPD patients, including no difference in heart-rhythm abnormalities or cardiovascular deaths.²⁰ However, a meta-analysis taking a broader view of all beta-2 agonists (short- and long-acting, across multiple drugs) found a roughly two-and-a-half-fold increased risk of cardiovascular events compared with placebo, driven mostly by faster heart rate.²¹ The discrepancy likely reflects that different beta-2 agonists have different cardiac profiles, and salmeterol at its approved dose appears safer in this regard than the class average. Still, if you have a pre-existing heart rhythm disorder or are on medications that affect heart rate, bring it up with your prescriber.

Getting the Inhaler Technique Right

The Inhub device that delivers Wixela is a dry powder inhaler, which means there is no propellant pushing the medication out. Instead, you generate the airflow by breathing in, and your inhalation pulls the powder into your lungs. This design eliminates the coordination problem of “press and breathe at the same time” that plagues pressurized metered-dose inhalers, but it introduces its own challenge: you need a sufficiently strong and deep inhalation to get the drug where it belongs.

Getting technique wrong with any dry powder inhaler is alarmingly common. Research has found that the proportion of patients making at least one critical error ranges widely, but in one large cross-sectional study of COPD patients, more than 80% made at least one critical mistake, and the more errors they made, the worse their health outcomes and the more flare-ups they experienced.²² A systematic review cataloged the most frequent dry powder inhaler errors: about 46% of users failed to exhale fully before inhaling the dose, 37% did not hold their breath afterward, and 29% prepared the device incorrectly.²³

For Wixela’s Inhub specifically, the basic steps matter more than they might seem:

Exhale fully first: Breathe all the way out away from the device before placing it to your mouth. This makes room in your lungs and ensures the inhalation that follows is deep enough to carry the powder down into the smaller airways.
Inhale fast and deep: Unlike a metered-dose inhaler where you breathe in slowly, dry powder inhalers need a quick, forceful breath. A weak inhalation means most of the drug lands in your throat instead of your lungs.²⁴
Hold your breath: After inhaling, hold your breath for about ten seconds (or as long as comfortable). This gives the fine particles time to settle into the lung tissue.
Rinse and spit: Rinse your mouth with water after every dose to reduce the corticosteroid deposited in your throat, which is the main driver of oral thrush and hoarseness.

Breathing in too fast has its own drawbacks with other inhaler types, but with dry powder inhalers, the bigger clinical problem is inhaling too weakly. Some patients with severe COPD or elderly patients with reduced lung capacity may struggle to generate enough airflow through any dry powder device. A usability study of the Inhub device tested it across pediatric, adult, and elderly patients with asthma or COPD, and found that the drug’s pharmaceutical performance was preserved after about three weeks of real-world use by these diverse groups.²⁵ If you find that your symptoms are not improving or you feel like you are not getting enough medication, ask your doctor or pharmacist to watch you use the device and correct any technique issues before assuming the drug itself is not working.

Cost Savings and Access

The financial impact of Wixela’s arrival has been significant. In its first year on the market, the availability of generic fluticasone-salmeterol was associated with roughly $941 million in total drug cost savings across this class of medications. The average unit cost of the approved generic was about $115, compared with $169 for the authorized generic marketed by the brand-name manufacturer and $334 for the branded Advair Diskus.²⁶ For individual patients, this can translate into noticeably lower copays, especially for those on high-deductible plans or without insurance.

The market dynamics around inhaler pricing have continued to evolve. In early 2024, brand-name inhaler manufacturers reduced their list prices, which had an unexpected side effect: by shrinking the room for large rebates that pharmacy benefit managers had previously negotiated, these list-price cuts actually made it easier for generics to compete, and generic use jumped by about 23 percentage points overall.²⁷ The upshot is that if you or your insurer were still paying brand-name prices for Advair, the landscape has shifted substantially in favor of generics like Wixela, and it is worth asking your pharmacist or checking your formulary.

The Environmental Angle

One advantage of Wixela that rarely comes up in a doctor’s office is its carbon footprint. As a dry powder inhaler, Wixela does not use the hydrofluorocarbon propellants found in pressurized metered-dose inhalers. The difference in greenhouse gas emissions is dramatic. An analysis of inhaler prescriptions in one Italian region found that metered-dose inhalers collectively produced more than one million kilograms of CO₂-equivalent emissions per year, while dry powder inhalers in the same region generated only about 55,000 kilograms, roughly one-twentieth as much.²⁸ This does not mean anyone should switch inhaler types purely for environmental reasons if their current device is working well, but if you are already on a fluticasone-salmeterol combination delivered by a metered-dose inhaler, moving to Wixela’s dry powder format carries a genuinely lower environmental cost alongside equivalent clinical outcomes.

Why Generic Inhalers Took So Long

Patients sometimes wonder why generic inhalers lagged so far behind generic pills. The answer is partly regulatory and partly technical. For an oral tablet, proving bioequivalence usually just requires showing that the drug reaches the bloodstream at the same rate and concentration as the brand. Inhaled drugs, by contrast, exert their effects locally in the lung, with minimal blood absorption. This makes blood-level comparisons insufficient on their own. The FDA ultimately required a combined package of in vitro lab tests, pharmacokinetic blood-level studies, and clinical trials measuring actual lung-function endpoints to prove that a generic inhaler deposits the drug in the lungs in the same way the brand does.²⁹ Building that evidence package is expensive and time-consuming, which is why Advair enjoyed market exclusivity for years after its core patents expired. The regulatory pathway carved out for Wixela has since made it somewhat easier for other generic inhalers to follow.